{
    "xml": "<topic id=\"PHP3767\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/lamivudine\" basename=\"lamivudine\" title=\"LAMIVUDINE\">\n<title>LAMIVUDINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_399\" namespace=\"/interactions/list-of-drug-interactions/antivirals/lamivudine\">Lamivudine</xref>\n</p>\n<data name=\"vtmid\">108698001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_149321041\" title=\"Nucleoside reverse transcriptase inhibitors\">Nucleoside reverse transcriptase inhibitors</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34645\" title=\"NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS\" namespace=\"/drug-classes/nucleoside-reverse-transcriptase-inhibitors\">NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n<p outputclass=\"synonyms\">3TC</p>\r\n</body>\n<topic id=\"PHP74212\" outputclass=\"cautions\" rev=\"1.25\" parent=\"/drugs/lamivudine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74200\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/lamivudine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (lamivudine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74182\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/lamivudine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">muscle disorders</ph>; <ph outputclass=\"sideEffect\">nasal symptoms</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">rhabdomyolysis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74214\" outputclass=\"breastFeeding\" parent=\"/drugs/lamivudine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can be used with caution in women infected with chronic hepatitis B alone, providing that adequate measures are taken to prevent hepatitis B infection in infants.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74190\" outputclass=\"renalImpairment\" parent=\"/drugs/lamivudine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74166\" outputclass=\"monitoringRequirements\" parent=\"/drugs/lamivudine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>When treating chronic hepatitis B with lamivudine, monitor liver function tests every 3 months, and viral markers of hepatitis B every 3&#8211;6 months, more frequently in patients with advanced liver disease or following transplantation (monitoring to continue for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58573\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/lamivudine\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Flavours of oral liquid formulations may include banana and strawberry.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3767-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/lamivudine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77106\" title=\"Tablet\" namespace=\"/drugs/lamivudine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77113\" title=\"Oral solution\" namespace=\"/drugs/lamivudine/oral-solution\">Oral solution</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP106633\" namespace=\"/drugs/abacavir-with-dolutegravir-and-lamivudine\" title=\"ABACAVIR WITH DOLUTEGRAVIR AND LAMIVUDINE\" count=\"1\" rel=\"backlink\">ABACAVIR WITH DOLUTEGRAVIR AND LAMIVUDINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85564\" namespace=\"/drugs/abacavir-with-lamivudine\" title=\"ABACAVIR WITH LAMIVUDINE\" count=\"1\" rel=\"backlink\">ABACAVIR WITH LAMIVUDINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85565\" namespace=\"/drugs/abacavir-with-lamivudine-and-zidovudine\" title=\"ABACAVIR WITH LAMIVUDINE AND ZIDOVUDINE\" count=\"1\" rel=\"backlink\">ABACAVIR WITH LAMIVUDINE AND ZIDOVUDINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85623\" namespace=\"/drugs/lamivudine-with-zidovudine\" title=\"LAMIVUDINE WITH ZIDOVUDINE\" count=\"1\" rel=\"backlink\">LAMIVUDINE WITH ZIDOVUDINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78240\" namespace=\"/treatment-summaries/hepatitis\" title=\"Hepatitis\" count=\"7\" rel=\"backlink\">Hepatitis</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78275\" namespace=\"/treatment-summaries/hiv-infection\" title=\"HIV infection\" count=\"2\" rel=\"backlink\">HIV infection</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_399\" namespace=\"/interactions/list-of-drug-interactions/antivirals/lamivudine\" title=\"Lamivudine\" count=\"1\" rel=\"link\">Lamivudine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34645\" namespace=\"/drug-classes/nucleoside-reverse-transcriptase-inhibitors\" title=\"NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS\" count=\"1\" rel=\"link\">NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77106\" namespace=\"/drugs/lamivudine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77113\" namespace=\"/drugs/lamivudine/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n</links>\n</topic>",
    "id": "PHP3767",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/lamivudine",
    "basename": "lamivudine",
    "title": "LAMIVUDINE",
    "interactants": [
        {
            "id": "bnf_int_399",
            "label": "Lamivudine"
        }
    ],
    "vtmid": "108698001",
    "drugClassification": [
        "Nucleoside reverse transcriptase inhibitors"
    ],
    "inheritsFromClass": [
        "NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "3TC"
    ],
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine",
                "html": "Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (lamivudine).",
                "html": "<p>Appendix 1 (lamivudine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "muscle disorders",
                        "html": "muscle disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nasal symptoms",
                        "html": "nasal symptoms",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rhabdomyolysis",
                        "html": "rhabdomyolysis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can be used with caution in women infected with chronic hepatitis B alone, providing that adequate measures are taken to prevent hepatitis B infection in infants.",
                "html": "<p>Can be used with caution in women infected with chronic hepatitis B alone, providing that adequate measures are taken to prevent hepatitis B infection in infants.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose if eGFR less than 50 mL/minute/1.73 m2; consult product literature.",
                "html": "<p>Reduce dose if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; consult product literature.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "When treating chronic hepatitis B with lamivudine, monitor liver function tests every 3 months, and viral markers of hepatitis B every 3&#8211;6 months, more frequently in patients with advanced liver disease or following transplantation (monitoring to continue for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation).",
                "html": "<p>When treating chronic hepatitis B with lamivudine, monitor liver function tests every 3 months, and viral markers of hepatitis B every 3&#8211;6 months, more frequently in patients with advanced liver disease or following transplantation (monitoring to continue for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation).</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Flavours of oral liquid formulations may include banana and strawberry.",
                "html": "<p>Flavours of oral liquid formulations may include banana and strawberry.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77106",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77113",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP106633",
                "label": "ABACAVIR WITH DOLUTEGRAVIR AND LAMIVUDINE",
                "type": "drug"
            },
            {
                "id": "PHP85564",
                "label": "ABACAVIR WITH LAMIVUDINE",
                "type": "drug"
            },
            {
                "id": "PHP85565",
                "label": "ABACAVIR WITH LAMIVUDINE AND ZIDOVUDINE",
                "type": "drug"
            },
            {
                "id": "PHP85623",
                "label": "LAMIVUDINE WITH ZIDOVUDINE",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78240",
                "label": "Hepatitis",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78275",
                "label": "HIV infection",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_399",
                "label": "Lamivudine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34645",
                "label": "NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77106",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77113",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    }
}